Common Mechanisms in Autoimmunity Insight Awards support researchers studying shared and distinct autoimmune mechanisms to generate proof-of-concept data and advance therapeutic targets and strategies.
Funder: Breakthrough T1D
Due Dates: January 7, 2027 (Proposal, 5:00 p.m. Eastern Standard Time)
Funding Amounts: Up to $150,000 for one year, including up to 10% indirect costs
Summary: Supports proof-of-concept pilot studies of shared and distinct autoimmune mechanisms to advance therapeutic targets and strategies.
Key Information: Projects must address pathways or targets relevant to all three: MS, SLE or a manifestation, and T1D.
Breakthrough T1D, Lupus Research Alliance, and the National Multiple Sclerosis Society jointly fund one-year pilot studies exploring commonalities and differences in autoimmune pathways. The awards support research into disease mechanisms, novel targets, target validation, and innovative therapeutic strategies. Projects should generate proof-of-concept data for larger, multi-year collaborative studies spanning autoimmune fields and disciplines.
Priority areas include human biomarkers measurable before clinical diagnosis, therapies targeting autoimmune initiation and early disease, and mechanisms explaining heterogeneity in autoimmune processes and disease presentation. The program also prioritizes primary human samples or existing human sample data, repurposing approved therapies across autoimmune diseases, and understanding shared or differing treatment responses.